NCI-H727 Xenograft Model Service for NSCLC
The NCI-H727 xenograft model serves as a well-characterized preclinical platform for evaluating therapeutic candidates against non-small cell lung cancer (NSCLC) with neuroendocrine features, enabling researchers to assess tumor growth dynamics, drug pharmacokinetics, and treatment efficacy in a physiologically relevant setting. Alfa Cytology delivers comprehensive NCI-H727 xenograft model services backed by rigorous quality control, standardized protocols, and multidisciplinary expertise to accelerate your preclinical oncology pipeline from candidate screening to mechanism-of-action validation.
Overview of NCI-H727 Xenograft Model for NSCLC
The NCI-H727 cell line was originally established from a primary bronchial carcinoid tumor and is classified as a typical pulmonary neuroendocrine neoplasm. While historically categorized under the broad umbrella of lung carcinoids, this line harbors molecular alterations—including KRAS mutations and aberrant mTOR pathway activation—that overlap with subsets of non-small cell lung cancer, making it a versatile surrogate for investigating neuroendocrine-differentiated NSCLC. In immunodeficient murine hosts, NCI-H727 cells form reproducible subcutaneous or orthotopic tumors that retain neuroendocrine marker expression such as chromogranin A, synaptophysin, and somatostatin receptor subtype 2 (SSTR2), thereby preserving the histopathological fidelity required for translational research.
Fig 1. An illustration of the subcutaneous NCI-H727 murine xenograft model. (Knigin, Adi, et al., 2021)
Xenograft studies utilizing NCI-H727 have demonstrated dose-dependent responses to targeted agents including mTOR inhibitors, tyrosine kinase inhibitors, and peptide-receptor radionuclide therapies. The model supports longitudinal tumor volume monitoring via caliper measurement or advanced imaging modalities, and tumor tissues harvested at endpoint are amenable to immunohistochemistry, Western blotting, flow cytometry, and genomic profiling. These attributes position the NCI-H727 xenograft as a robust intermediate between in vitro assays and more complex patient-derived models, offering a balance of throughput, reproducibility, and clinical relevance for preclinical drug development.
Cell Line Information: NCI-H727
NCI-H727 is a human bronchial carcinoid cell line with well-differentiated neuroendocrine characteristics. Derived from a primary pulmonary carcinoid tumor, this line exhibits epithelial morphology, robust anchorage-dependent growth, and consistent tumorigenicity in immunodeficient mice. The following table summarizes the key attributes of the NCI-H727 cell line relevant to xenograft model development.
| Parameter |
Details |
| Cell Line Name |
NCI-H727 |
| ATCC Catalog No. |
CRL-5815 |
| Tumor Origin |
Primary bronchial carcinoid (typical carcinoid) |
| Histological Classification |
Well-differentiated pulmonary neuroendocrine neoplasm |
| Species |
Human (Homo sapiens) |
| Age / Gender |
35-year-old male |
| Morphology |
Epithelial; adherent monolayer |
| Culture Medium |
RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine |
| Key Molecular Features |
KRAS mutation; mTOR pathway activation; SSTR2 expression; chromogranin A and synaptophysin positive |
| Doubling Time |
Approximately 48–60 hours under standard culture conditions |
| Tumorigenicity |
High; forms palpable subcutaneous tumors in athymic nude mice within 14–21 days |
| Recommended Inoculum |
4 × 10⁶ cells per mouse in 100–200 µL PBS/Matrigel mixture (1:1) |
| Host Strain |
Athymic nude mice (nu/nu) or NOD/SCID mice, 6–8 weeks old |
| Tumor Growth Characteristics |
Slow-to-moderate growth; mean tumor volume doubling time approximately 7–10 days |
| Endpoint Tumor Volume |
Typically 1,000–1,500 mm³ or per institutional animal welfare guidelines |
| Applications |
Drug efficacy screening, pharmacokinetic studies, biomarker validation, combination therapy assessment, radionuclide therapy evaluation |
Our Services
Alfa Cytology provides end-to-end NCI-H727 xenograft model services tailored to your preclinical research objectives. Our team manages every phase—from cell line authentication and health monitoring to tumor inoculation, randomized group allocation, compound administration, and comprehensive endpoint analysis—ensuring data integrity and regulatory compliance throughout your study. With flexible scheduling, real-time tumor tracking, and customizable readout panels, we help you generate publication-quality datasets that advance your therapeutic programs with confidence.
Workflow of NCI-H727 Xenograft Model Construction
Construction of the NCI-H727 xenograft model follows a systematic, quality-controlled workflow designed to ensure tumor take rates, reproducible growth kinetics, and ethical compliance. Each stage is executed under GLP-aligned standard operating procedures with documented batch records and traceability.
- Cell Line Preparation and Quality Control: NCI-H727 cells are expanded from authenticated cryopreserved stocks and tested for mycoplasma contamination, viability, and passage consistency. Cells are harvested at logarithmic growth phase and resuspended in ice-cold PBS or a PBS/Matrigel matrix immediately prior to inoculation.
- Animal Preparation and Randomization: Immunodeficient mice (athymic nude or NOD/SCID) are acclimated for a minimum of five days, then randomized into treatment and control cohorts based on body weight. All procedures are approved by the institutional animal care and use committee (IACUC).
- Tumor Cell Inoculation: A suspension of 4 × 10⁶ NCI-H727 cells is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. Alternatively, orthotopic implantation into the lung parenchyma may be performed for studies requiring organ-specific microenvironment interactions.
- Tumor Monitoring and Caliper Measurement: Tumor dimensions are measured with digital calipers twice weekly starting from the appearance of palpable masses. Tumor volume is calculated using the modified ellipsoid formula: length × (width)² / 2. Body weight and clinical signs are recorded concurrently.
- Compound Administration and Dosing: Test articles are administered via the designated route (oral gavage, intraperitoneal, intravenous, or subcutaneous) according to the study-specific dosing regimen. Vehicle controls receive the equivalent formulation without active compound.
- Endpoint Assessment and Tissue Collection: Upon reaching the predetermined endpoint—typically when tumor volume approaches 1,500 mm³ or at a fixed study duration—mice are humanely euthanized. Tumors are excised, weighed, and partitioned for formalin-fixed paraffin-embedded (FFPE) histology, snap-frozen molecular analysis, and cell dissociation for flow cytometry.
- Data Analysis and Reporting: Tumor growth curves, tumor growth inhibition (TGI) percentages, and statistical comparisons between groups are generated using validated biostatistical software. A comprehensive study report including raw data, methodology, and representative images is delivered to the sponsor.
Fig 2. NCI-H727 xenograft model construction workflow.
Case Study-NCI-H727 Xenograft Model Development
In a recent preclinical engagement, the NCI-H727 xenograft model was employed to evaluate the anti-tumor activity of a dual-targeting therapeutic regimen. Following subcutaneous inoculation of 4 × 10⁶ cells into athymic nude mice, palpable tumors were established within 18 days with a take rate exceeding 90%. Animals were randomized into vehicle, monotherapy, and combination arms, with compound dosing initiated when mean tumor volume reached approximately 150 mm³. Longitudinal monitoring revealed differential growth inhibition across treatment groups, and endpoint analysis demonstrated modulation of neuroendocrine markers and downstream signaling pathways in tumor lysates. Histopathological examination confirmed preserved SSTR2 expression and reduced Ki-67 proliferative indices in responder cohorts. These findings supported the advancement of the therapeutic candidate into subsequent IND-enabling studies.
Why Choose Alfa Cytology?
Partnering with Alfa Cytology for your NCI-H727 xenograft studies means gaining access to a fully integrated preclinical infrastructure that prioritizes scientific rigor, operational transparency, and timely delivery. Our differentiated capabilities ensure that every study generates actionable insights.
- Authenticated cell banks with routine STR profiling and mycoplasma screening to guarantee model fidelity.
- Customizable study designs including subcutaneous, orthotopic, and metastatic model configurations.
- Real-time tumor tracking with digital calipers or non-invasive imaging (bioluminescence, MRI, or micro-CT) upon request.
- Multiplex endpoint analysis encompassing histopathology, IHC, Western blot, qPCR, flow cytometry, and cytokine profiling.
- Dedicated project managers providing weekly progress updates, raw data access, and regulatory-compliant documentation.
- Competitive timelines with standard tumor establishment studies completed within 4–6 weeks from study initiation.
Contact Us
Ready to advance your preclinical NSCLC program with a validated NCI-H727 xenograft model? Reach out to our scientific team today to discuss your study objectives, receive a tailored proposal, and explore how Alfa Cytology can accelerate your path from bench to bedside. Contact us now to schedule a consultation and take the next step toward robust, reproducible preclinical data.
Reference
- Knigin, Adi, et al. "The autophagy inhibitor chloroquine, alone or in combination with mTOR inhibitors, displays anti-tumor effects in in vitro and in vivo lung carcinoid models." Cancers 13.24 (2021): 6327.
For research use only. Not intended for any clinical use.
